Croma Skincare – Where Science Meets Skin
26.5.2026 12:43:00 EEST | Business Wire | Press release
With Croma Skincare, Austrian family-owned company Croma Pharma translates decades of expertise in aesthetic medicine into a modern skincare line designed for everyday results. Rather than following short-lived trends, Croma focuses on scientifically proven ingredients and pharmaceutical-grade formulations that deliver visible performance while fitting seamlessly into daily routines.
Building on 50 years of experience in hyaluronic acid, Croma Pharma developed this skincare range to bridge the gap between in-clinic treatments and at-home care. The result is a streamlined portfolio that supports key skin needs such as hydration, glow, balance, and protection.
The formulations combine high-performance actives including niacinamide, peptides, hyaluronic acid, and plant stem cells with lightweight, fast-absorbing textures that strengthen the skin barrier and enhance overall skin health.
Hero products include:
- THE GLOW - a 20% stabilized vitamin C serum for radiance, antioxidant protection, and a more even complexion
- THE EVERYDAY - balancing daily care for healthy-looking skin
- THE SHIELD - protective hydration for urban lifestyles
- THE SUNKISSED - mineral sun protection designed for daily wear
All products are vegan, dermatologically tested, and free from microplastics, reflecting Croma's commitment to quality, safety, and responsible formulation.
Croma Skincare is available via the official webshop and selected partners, as well as through local Croma Pharma representatives.
https://www.cromaskincareshop.com
About Croma
CROMA-PHARMA GmbH is a global player and challenger in the dynamically growing minimally invasive aesthetics market, and one of Europe’s leading manufacturers of premium-quality hyaluronic acid (HA) syringes. Founded in 1976 by the pharmacist couple Gerhard and Karin Prinz, Croma has evolved from a family pharmacy into a globally operating Austrian company headquartered near Vienna, where it also runs its state-of-the-art, fully automated HA manufacturing plant. The company employs around 400 people, making its products available in over 80 countries worldwide. Croma offers a comprehensive and innovative aesthetics portfolio covering all key treatment categories in minimally invasive aesthetic medicine. Its range includes botulinum toxin, a broad selection of hyaluronic acid fillers, lifting threads (PDO threads), polynucleotide injectables, HA skin booster, skincare, as well as autologous PRP I Fluid‑PRF medical device. With this full‑face approach, Croma provides aesthetic professionals and their patients with safe, effective, and reliable solutions from a single trusted source. In 2025, the company surpassed 110 million syringes produced, further strengthening its position as one of Europe’s leading HA manufacturers. Building on its heritage in orthopedics and ophthalmology, Croma is re-entering the orthopedics market in 2026, marking a strategic expansion beyond aesthetics and reinforcing its roots in medical applications.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260520830163/en/
Contacts
Press contact:
CROMA-PHARMA GmbH
Victoria Szafraniec
Global Digital Media & PR Manager
Cromazeile 2
A-2100 Leobendorf
Phone: +43 676 846 868 494
Mail: victoria.szafraniec@croma.at
Web: www.cromapharma.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.cromapharma
.com&esheet=54539123&newsitemid=20260520830163&lan=en-US&anchor=www.cromapharma.
com&index=2&md5=20ffa5e167fc7236536f9dcf5ab83380
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference26.5.2026 13:01:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, with a fireside chat at 10:00 a.m. EDT. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. An archived webcast will be available on the Company’s website. About BeOne BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.beonemedicines.com
GlobalPlatform Launches Pavona: The First Open Silicon Distribution with Production-Grade Post-Quantum Cryptography26.5.2026 13:00:00 EEST | Press release
GlobalPlatform today launched Pavona, an open-source silicon distribution that delivers production-quality, certification-ready IP components and reference top-level designs — including the first openly available post-quantum cryptography (PQC) stack for embedded silicon. The distribution includes two successfully taped-out reference designs—a standalone chip root of trust and an integrated root of trust for chiplet architectures fabricated at TSMC 3nm (N3). Pavona provides a composable framework for building secure-by-default silicon aligned with FIPS 140-3 and Common Criteria certification requirements. Twelve founding members have already committed to the initiative, spanning semiconductor manufacturers, AI companies, academic research institutions, and IP providers. The full IP repository, top-level designs, continuous integration dashboards and getting-started documentation are available today at www.pavona.org. “The world faces a rising tide of cyber insecurity, with mounting cos
Ant International’s Alipay+ Enables Mobile Payments for Global Travellers in Latin America26.5.2026 12:40:00 EEST | Press release
Alipay+, a leading global payment gateway under Ant International that connects 150 million global merchants and 2 billion consumer accounts, is rolling out cross-border mobile payment services for global travellers in Latin America in collaboration with PVS, a fintech company specialized in developing customized payment solutions in the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526146133/en/ Facilitated by Alipay+ and PVS, travellers from Asia and Europe can now use their familiar home e-wallets and banking apps to make QR code payments at PVS merchants, starting with initial rollouts in Chile and Argentina. This partnership enables users of Alipay+’s partner payment apps, including 50 e-wallets and banking apps, and over 10 national QR schemes, to make seamless QR payments at PVS merchants. The collaboration aims to support global travellers, especially those from Asia who are increasingly exploring multipl
LTM to Drive AI-Powered Modernization of IT Infrastructure and Application Support for UK-based SSP Group26.5.2026 12:00:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, has entered a strategic partnership with SSP Group, a leading operator of food and beverage outlets in travel locations worldwide. Through this AI-powered partnership, LTM will deliver modernized, end-to-end IT infrastructure support and enhanced application maintenance services to SSP Group. As part of this engagement, LTM will leverage its advanced AI capabilities including its BlueVerseTM ecosystem to help SSP manage operational risks, simplify infrastructure and application complexities, and drive business efficiency and agility. Additionally, the collaboration will focus on enabling data-driven decision-making, accelerating innovation through automation, delivering scalable solutions that enhance customer experience, and driving cost optimization through AI automation and simplification. “As we continue to advance our IT capabilities, having a trusted partner like LTM with deep domain expertise and a focus on
ROYC and Stilla Enter Strategic Partnership to Operationalise Agentic AI in Private Markets26.5.2026 11:30:00 EEST | Press release
ROYC today announced a partnership with Stilla.ai as the platform layer where ROYC will create, share and run its internally developed AI skills and agents. This operationalises the agentic AI strategy ROYC set out earlier, equipping every function across the company with the tools and resources to build and deploy their own AI agents and converting this into measurable productivity gains and accelerated product development. This will substantially accelerate launch of new platform features, improving cost efficiency at the same time as strengthening overall governance and oversight. For ROYC’s customers and partners, the result will be shorter time-to-market for new product releases, shorter time frames moving from idea to productification and tailored customer experience from an investor services perspective. “Our strategy is clear: AI is embedded in every aspect of our ways of working and what the ROYC Operating System does, not a side project,” said Peter Bergenwald, CTO of ROYC. “
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom